Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer
Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reapp...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/4/732 |
_version_ | 1797436839139737600 |
---|---|
author | Lorena García-Hevia Débora Muñoz-Guerra Íñigo Casafont Carmelo Morales-Angulo Victor J. Ovejero David Lobo Mónica L. Fanarraga |
author_facet | Lorena García-Hevia Débora Muñoz-Guerra Íñigo Casafont Carmelo Morales-Angulo Victor J. Ovejero David Lobo Mónica L. Fanarraga |
author_sort | Lorena García-Hevia |
collection | DOAJ |
description | Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer. |
first_indexed | 2024-03-09T11:08:23Z |
format | Article |
id | doaj.art-b03c6de67d61466b8de6271ac2a9441d |
institution | Directory Open Access Journal |
issn | 2227-9059 |
language | English |
last_indexed | 2024-03-09T11:08:23Z |
publishDate | 2022-03-01 |
publisher | MDPI AG |
record_format | Article |
series | Biomedicines |
spelling | doaj.art-b03c6de67d61466b8de6271ac2a9441d2023-12-01T00:52:29ZengMDPI AGBiomedicines2227-90592022-03-0110473210.3390/biomedicines10040732Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck CancerLorena García-Hevia0Débora Muñoz-Guerra1Íñigo Casafont2Carmelo Morales-Angulo3Victor J. Ovejero4David Lobo5Mónica L. Fanarraga6The Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainServicio de Otorrinolaringología, Hospital Universitario Marqués de Valdecilla, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainHead and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer.https://www.mdpi.com/2227-9059/10/4/732gangliosidecancerresistancesquamous cell carcinoma |
spellingShingle | Lorena García-Hevia Débora Muñoz-Guerra Íñigo Casafont Carmelo Morales-Angulo Victor J. Ovejero David Lobo Mónica L. Fanarraga Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer Biomedicines ganglioside cancer resistance squamous cell carcinoma |
title | Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer |
title_full | Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer |
title_fullStr | Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer |
title_full_unstemmed | Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer |
title_short | Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer |
title_sort | gb3 cd77 is a predictive marker and promising therapeutic target for head and neck cancer |
topic | ganglioside cancer resistance squamous cell carcinoma |
url | https://www.mdpi.com/2227-9059/10/4/732 |
work_keys_str_mv | AT lorenagarciahevia gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer AT deboramunozguerra gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer AT inigocasafont gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer AT carmelomoralesangulo gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer AT victorjovejero gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer AT davidlobo gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer AT monicalfanarraga gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer |